Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
BioLineRx financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.4
2024-10-29
Market Capitalization
$38.5 M
2024-10-29
Revenue
$1.2 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.8M | 28.9M | 1.2M | |||||
| Cost of goods sold | 3.7M | 9.5M | 230.0K | |||||
| Gross profit | 1.1M | 19.4M | 950.0K | |||||
| Gross profit margin, % | 67.0% | 80.5% | ||||||
| Operating expense total | 25.1M | 27.5M | 22.4M | 24.3M | 28.8M | 43.2M | 37.3M | 11.5M |
| Depreciation and amortization | 545.0K | 565.0K | 548.0K | 496.0K | 389.0K | 7.6M | 1.8M | 523.0K |
| EBITDA | (25.1M) | (27.5M) | (22.4M) | (24.3M) | (28.8M) | (42.1M) | (17.9M) | (10.6M) |
| EBITDA margin, % | -61.7% | -895.3% | ||||||
| EBIT | (25.5M) | (28.6M) | (23.5M) | (24.7M) | (29.9M) | (49.5M) | (20.1M) | (11.6M) |
| EBIT margin, % | -69.6% | -983.8% | ||||||
| Interest income | 719.0K | 777.0K | 236.0K | 559.0K | 694.0K | 2.0M | 1.8M | 1.1M |
| Interest expense | 452.0K | 1.8M | 1.5M | 984.0K | 1.8M | 2.1M | 9.1M | 1.3M |
| Pre tax profit | (23.0M) | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (9.2M) | (2.0M) |
| Net Income | (23.0M) | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (9.2M) | (2.0M) |